CureVac Appoints International Financial Expert Michael Brosnan as Auditor


Tübingen, Germany and Boston, Massachusetts / ACCESSWIRE / June 20, 2023 / CureVac NV (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of innovative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as its director. announced the appointment of an independent director of the division. board. Brosnan will succeed Hans-Christoph Tanner, who has been a member of CureVac’s Supervisory Board since 2015. Mr. Michael Brosnan was appointed at the CureVac Annual Meeting on June 19, 2023.

“Michael is an excellent addition to the CureVac board of directors. His global financial and audit experience will help us manage financial stability as we move toward late-stage clinical development and commercialization.” said Jean-Stéphane, Chairman of the CureVac Supervisory Board. “We sincerely thank Hans Christoph for his dedication and guidance over the past eight years and wish him the best of luck in the future.”

Mr. Brosnan is a highly regarded international financial expert with extensive experience in executive and non-executive finance committee roles and as an auditor. He is currently a member of the Supervisory Board and chairman of the Audit Committee of MorphoSys AG. He is also a member of the Supervisory Board and Chairman of the Audit Committee of Daimler Trucks AG. Until his retirement in 2019, he served as his CFO of Fresenius Medical Care Management AG. He was an audit partner at KPMG before taking over management of the finance department. Mr. Brosnan holds a degree in business administration and accounting from Northeastern University in Boston.

“CureVac is a pioneer in the mRNA field and I am delighted to join the company at a time of extraordinary growth and progress,” said Brosnan. “I look forward to working with the Supervisory Board members and management team to help bring this transformative technology to life.”

About Cure Back

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with over 20 years of expertise in developing, optimizing and manufacturing this versatile biomolecule for medical purposes. I have. The principle of CureVac’s proprietary technology is to use optimized mRNAs as data carriers to instruct the body to produce unique proteins that can fight a wide range of diseases. In July 2020, CureVac partnered with GSK to jointly develop a new product for the prevention of infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation novel coronavirus disease (COVID-19) vaccine candidates and modified mRNA vaccine technology. Based on proprietary technology, CureVac has built a deep clinical pipeline spanning preventive vaccines, cancer therapies, antibody therapies and rare disease treatments. Headquartered in Tübingen, Germany, CureVac NV has over 1,100 employees in Germany, the Netherlands, Belgium, Switzerland and the USA. For more information, please visit

Contact CureVac Media and Investor Relations

Dr. Sarah Fakih, Vice President of Corporate Communications and Investor Relations
CureVac, Tubingen, Germany
Phone: +49 7071 9883-1298
Male: +49 160 90 496949

Forward-Looking Statements CureVac

This press release contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the opinions, expectations, beliefs, plans and objectives of CureVac NV. Includes statements that express assumptions, assumptions, or projections. and/or any future event or future of its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands BV (the “Company”); Contrary to statements that reflect historical facts, the results are as follows: Examples include statements regarding the completion, size and terms of the proposed public offering. In some cases, such forward-looking statements are defined as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “plan,” or “expect.” can be identified by terms such as “may,” “would,” “would,” “could,” “could,” “intend,” or “should,” any of these terms Denial or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and information currently available to the company. However, these forward-looking statements are not guarantees of the company’s performance and undue reliance should not be placed on such statements. Forward-looking statements are subject to a number of risks, uncertainties and other changes. This includes negative global economic conditions, continued volatility and volatility in global financial markets, ability to raise capital, and ability to conduct current and future preclinical research and clinical trials. timing, costs and uncertainties of regulatory approvals; reliance on third parties and alliance partners; ability to commercialize products; ability to manufacture any product; current and proposed changes in laws, regulations and governmental policies; industry pressures from increased competition and internal consolidation; impact of the COVID-19 pandemic on our business and results of operations; ability to manage growth; reliance on key personnel; Dependencies, our ability to provide patient safety, and performance fluctuations due to the impact of COVID-19. the effect of exchange rates or other factors; Such risks and uncertainties could cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are beyond our control and actual results may differ materially from those we anticipate. The forward-looking statements contained in this press release are made only as of the date of this press release. The Company undertakes no obligation to update such statements to reflect future events or developments or to publish the results of revising such statements, except as required by law. specifically refuse.

For more information, see the company’s report and documents filed with the US Securities and Exchange Commission (SEC). These documents are available by visiting EDGAR on the SEC website at

sauce: Cure Back NV

View the source version on

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *